ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ANALYSIS

Organ Transplant Immunosuppressant Drugs MarketSize and Trends

Global organ transplant immunosuppressant drugs market is estimated to be valued at US$ 5.17 billion in 2023 and is expected to exhibit a CAGR of 3.1% during the forecast period (2023-2030).

Figure 1. Global Organ Transplant Immunosuppressant Drugs Market Share (%), By Drug Class, 2023

Global Organ Transplant Immunosuppressant Drugs Market - Drivers

• Increasing incidences of chronic diseases: Increasing incidences of chronic diseases is expected to propel the growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, according to World Health Organization (WHO) report published in September 2022, chronic diseases account for 41 million annual fatalities, or 74% of all fatalities worldwide. The majority of chronic diseases or non- communicable diseases (NCDs), with 17.9 million fatalities each year, which are caused by cardiovascular illnesses, followed by malignancies like cancer and tumor (9.3 million), chronic respiratory conditions (4.1 million), and diabetes (2.0 million, including deaths from renal disease brought on by diabetes).
• Increasing geriatric population: Ageing is associated with a higher risk of organ failure, as many organs naturally decline in function with age. Common age-related organ failures include kidney, heart, liver, and lung diseases. As people age, they are more likely to require organ transplants to extend their lives, thus increasing the demand for immunosuppressant drugs. For instance, according to World Health Organization report published in October 2022,  in 2020, there will be more persons over 60 than under five-year-olds. The percentage of people over 60 in the world will nearly treble from 12% to 22% between 2015 and 2050.

Global Organ Transplant Immunosuppressant Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

The pandemic disrupted global supply chains, affecting the availability of pharmaceutical raw materials and finished products. This led to potential shortages of immunosuppressant drugs, which could have affected transplant patients. Many hospitals and healthcare facilities postponed or scaled back non-essential medical procedures, including organ transplant surgeries, to allocate resources for COVID-19 patients. This had an immediate impact on the demand for immunosuppressant drugs.

The COVID-19 pandemic had a significant worldwide influence on solid organ transplantation (SOT). According to National Center for Biotechnology Information report published in July 2022, in 2020, there was an approximate 16% decrease in transplant procedures globally, with kidney transplants and living donor programs being the most severely affected. Moreover, an analysis study published in National Center for Biotechnology Information (NCBI) article, solid organ transplantation (SOT) rates in 22 countries in 2019 and 2020 predicted a 16% global decline in transplant activity, with the biggest drop occurring in the first three months of the pandemic.

According to Lancet report 2020, at all phases of the donation procedure, there have been decreases in transplant activity, with the majority of data coming from the beginning of the epidemic. First, it was reported that in 2020, donor referrals decreased by 12% to 39%.

Additionally, many hospitals and healthcare facilities postponed or scaled back non-essential medical procedures, including organ transplant surgeries, to allocate resources for COVID-19 patients. This had an immediate impact on the demand for immunosuppressant drugs. Overall, the COVID-19 pandemic had a negative impact on the organ transplant immunosuppressant drugs market. It disrupted supply chains, delayed transplant procedures, raised concerns among transplant recipients, prompted research, and led to regulatory changes.

Figure 2. Global Organ Transplant Immunosuppressant Drugs Market Share(%), By Region, 2023

Global Organ Transplant Immunosuppressant Drugs Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global organ transplant immunosuppressant drugs market over the forecast period. Major pharmaceutical companies and biotech firms in North America are actively involved in the production and distribution of immunosuppressant drugs. These companies invest heavily in research and development to create more effective and safer drugs. For instance, in September 2021, Sanofi, a global healthcare company and Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops, and offers revolutionary treatments for disease areas with high unmet medical needs, have signed a final merger agreement. RezurockTM (belumosudil) will be added right away to Sanofi's transplant portfolio as part of the acquisition, which complements the company's ambition to expand its core General Medicines assets.